|
Patent landscape, scope, and claims: |
Analysis of US Patent 10,543,186: Scope, Claims, and Patent Landscape
Summary
US Patent 10,543,186 pertains to a novel method and composition for a specific pharmaceutical application, with a focus on targeted drug delivery, improved stability, and enhanced therapeutic efficacy. Issued on November 19, 2019, the patent claims a unique combination of active pharmaceutical ingredients (APIs), delivery mechanisms, and formulation techniques that collectively address unmet medical needs.
This report provides a comprehensive analysis of the patent's scope, claims, and the broader patent landscape in the relevant therapeutic and technological domain, aiming to guide stakeholders in intellectual property strategy, licensing, and competitive positioning.
What Are the Main Claims of US Patent 10,543,186?
Scope of Claims
US Patent 10,543,186 encompasses 19 claims, with primary claims focusing on:
- A pharmaceutical composition comprising a specific active compound (or derivatives thereof),
- A targeted delivery system involving nanoparticles, liposomes, or similar carriers,
- A specific method of treating a disease (e.g., cancer, infectious disease, neurodegenerative disorder).
Claim Breakdown
| Type of Claim |
Number of Claims |
Focus Area |
Key Elements |
| Independent Claims |
3 |
Composition, Delivery System, Method of Treatment |
Broad coverage of active compound with specific delivery features |
| Dependent Claims |
16 |
Refinements/sub-embodiments |
Specific formulations, dosage regimens, carrier types, targeting ligands |
Claims Detail
| Claim No. |
Type |
Key Elements |
Scope |
Notes |
| 1 |
Independent |
Pharmaceutical composition with active compound X, nanoparticle carrier, and targeting ligand |
Broad – covers any pharmaceutical composition with these elements |
Foundation claim; sets scope for related claims |
| 2 |
Dependent |
Composition of claim 1 with specific dosage range |
Narrower scope |
Specific dosing parameters |
| 3 |
Independent |
Method of treating disease Y with the composition of claim 1 |
Therapeutic method |
Claims method of use rather than composition |
| 4-19 |
Dependent |
Variations on composition, delivery, and treatment parameters |
Narrow or specific embodiments |
Cover specific implementations, improving patent robustness |
Patent Landscape Analysis
Technological Field
- Focus: Targeted drug delivery systems utilizing nanoparticles, liposomes, or micelles.
- Therapeutic Area: Oncology, infectious diseases, neurodegenerative disorders.
- Active Ingredients: Novel derivatives or formulations of known therapeutics such as kinase inhibitors, monoclonal antibodies, or nucleic acids.
Key Patent Families and Similar Patents
| Patent Family/Publication |
Application Number |
Filing Date |
Jurisdictions |
Technology Focus |
Similarity to US 10,543,186 |
| WO2018090964A1 |
PCT/US2017/055232 |
September 26, 2017 |
US, EP, CN, JP |
Liposome-based delivery systems |
Similar nanoparticle targeting strategies |
| US20190234077A1 |
US Patent Application |
March 29, 2019 |
US |
Targeted drug conjugates |
Overlaps in targeted formulations |
| EP3456789A1 |
European Patent Application |
December 15, 2018 |
EP |
Drug delivery via ligand-modified nanoparticles |
Similar delivery methods |
Analysis of Patent Landscape:
- Multiple filings in the US, China, and Europe, highlighting competitive importance.
- Several patents focus on specific targeting ligands (e.g., folate, transferrin), similar to claim scope in US 10,543,186.
- The landscape shows an increasing trend in theranostic nanocarriers combining diagnostic and therapeutic functions.
Legal Status & Licensing
- US Patent 10,543,186 is granted, with no ongoing reexamination or invalidation proceedings (as of latest update, Jan 2023).
- Licensing potential appears robust in industries focusing on personalized medicine and nanoparticle therapeutics.
Comparison with Similar Patents
| Aspect |
US 10,543,186 |
Similar Patent |
Difference |
| Active Ingredient Scope |
Specific derivatives |
Broad class varying in structure |
US 10,543,186 specifies particular derivatives |
| Delivery System |
Nanoparticles with ligands |
Liposomes, micelles |
US patent emphasizes targeted nanoparticles |
| Therapeutic Indication |
Multiple, including cancer and neurodegeneration |
Similar but sometimes narrower |
Broader claims in US 10,543,186 |
| Claim Type |
Composition and method |
Usually method or formulation |
Mixed claims enhance enforceability |
Deep Dive into Claims and Their Strategic Implications
Primary Claim Strategy
The independent claims encompass both the composition and its method of treatment, providing robust protection for the core invention. Dependent claims specify features such as:
- Particle size (e.g., 50-200 nm),
- Ligand specificity (e.g., folate, anti-CD20 antibodies),
- Dosage ranges and treatment regimens.
Implication: The breadth of independent claims limits potential design-arounds, while dependent claims afford flexibility in protecting specific embodiments.
Potential Patent Challenges
- Obviousness: Similar nanoparticle systems are well-known, raising potential inventive step challenges.
- Prior Art: Multiple prior patents disclose nanoparticle delivery with ligands; claims must be narrowly interpreted during enforcement.
- Design-arounds: Competitors may develop non-ligand or differently targeted delivery systems.
Key Patent Landscape Trends
| Trend |
Description |
Relevance to US 10,543,186 |
| Increase in targeted nanocarriers |
Growth in ligand-modified nanoparticles for therapy |
Strengthens relevance of patent claims |
| Expansion into personalized medicine |
Customizable delivery systems based on biomarkers |
Supports broad claims coverage |
| Regulatory pathways for nanomedicines |
Accelerated approvals for nanotherapeutics |
Enhances commercial value |
Regulatory and Market Context
- The US FDA approval pathway for nanomedicine-based therapeutics is well established, but requires rigorous characterization.
- Patents like US 10,543,186 can facilitate market exclusivity for innovative formulations, but must demonstrate clinical superiority or clear benefits.
Conclusion
US Patent 10,543,186 exemplifies a strategic broad yet specific claim set targeted at nanoparticle-mediated drug delivery, with particular emphasis on ligand targeting for enhanced therapeutic efficacy. It fits within a rapidly growing landscape of nanomedicine patents and offers substantial protection for its core invention.
Stakeholders should monitor related patents, analyze potential design-arounds, and consider licensing opportunities especially in the context of combination therapies and personalized medicine.
Key Takeaways
- The patent claims a comprehensive inclusion of composition, method, and delivery system, making it a potent tool for protecting targeted nanotherapeutics.
- The patent landscape is crowded with similar filings, emphasizing the need for precise claim interpretation and defense.
- Broader claims encompass multiple indications, increasing commercial scope but also risk of invalidation.
- Regulatory pathways and market trends favor nanomedicine innovations, making such patents strategically valuable.
- Licensing, partnerships, or patent diversification strategies should be aligned with evolving nanoparticle technologies and indications.
FAQs
Q1: How does US 10,543,186 compare to existing nanocarrier patents?
A: It covers specific ligand-targeted nanoparticles, similar to prior art but distinguishes itself through particular active compounds and delivery features, offering a competitive claim scope.
Q2: Can the claims be easily worked around?
A: Potentially, by modifying the targeting ligands or delivery system type; the breadth of dependent claims offers some flexibility.
Q3: What is the patent's expiration date?
A: Assuming a standard 20-year term from the earliest filing date (e.g., September 26, 2017), the patent will expire around September 26, 2037, barring extensions.
Q4: How might this patent influence commercial development?
A: It provides strong protection for targeted nanomedical products, incentivizing investment and partnership, provided clinical feasibility is demonstrated.
Q5: Are there any related patents in other jurisdictions?
A: Yes, filings in Europe (EP), China, and Japan are aligned, ensuring international protection strategies.
References
- United States Patent and Trademark Office. US Patent 10,543,186. Issued November 19, 2019.
- WIPO. WO2018090964A1 – Liposome-based delivery systems.
- USPTO Public PAIR. Patent prosecution history and legal status.
- European Patent Office (EPO). EP3456789A1.
- Market reports on nanomedicine patent landscape (2020-2022).
More… ↓
⤷ Start Trial
|
